• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

    2/14/24 8:33:12 AM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGEN alert in real time by email
    SC 13G/A 1 deeptrack-agen123123a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    Agenus Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    00847G705

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  00847G705
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Capital, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    31,697,539
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    31,697,539
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    31,697,539
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.31%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  00847G705
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Deep Track Biotechnology Master Fund, Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    31,697,539
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    31,697,539
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    31,697,539
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.31%
    12
    TYPE OF REPORTING PERSON
     
    CO

     


     

    CUSIP No.  00847G705
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    David Kroin
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    31,697,539
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    31,697,539
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    31,697,539
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    8.31%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC
     


     

     

    CUSIP No. 00847G705
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Agenus Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    3 Forbes Road

    Lexington, MA 02421

    Item 2.(a) Names of Persons Filing:

    (i) Deep Track Capital, LP

    (ii) Deep Track Biotechnology Master Fund, Ltd.

    (iii) David Kroin 

      

    Item 2.( b) Address of Principal Business Office:

    (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

    (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands

    (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830

      

    Item 2.(c) Citizenship:

    (i) Delaware

    (ii) Cayman Islands

    (iii) United States

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.01 par value (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    00847G705

     

    CUSIP No.  00847G705
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

     

     

     

     

    CUSIP No. 00847G705
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2023, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    The amount beneficially owned by each Reporting Person is determined based on 381,495,471 Common Stock outstanding.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 00847G705
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
     
    CUSIP No. 00847G705
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Deep Track Capital, LP

           
      By:  /s/ David Kroin
        David Kroin, Managing Member of the General Partner of the Investment Adviser
           
     

    Deep Track Biotechnology Master Fund, Ltd.

     

     

     
      By:  /s/ David Kroin
        David Kroin, Director
           
     

    David Kroin

           
      By:  /s/ David Kroin
        David Kroin
           
    Get the next $AGEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AGEN

    DatePrice TargetRatingAnalyst
    6/4/2025$25.00Neutral → Buy
    H.C. Wainwright
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    7/18/2024Outperform → Mkt Perform
    William Blair
    7/18/2024$9.00Buy → Neutral
    H.C. Wainwright
    6/6/2023$8.00Outperform
    Robert W. Baird
    6/6/2023$60.00 → $80.00Outperform
    Robert W. Baird
    2/28/2023$8.00Buy
    H.C. Wainwright
    9/28/2022$5.00Outperform
    SMBC Nikko
    More analyst ratings

    $AGEN
    SEC Filings

    See more
    • Agenus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - AGENUS INC (0001098972) (Filer)

      6/20/25 4:10:27 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by Agenus Inc.

      DEFR14A - AGENUS INC (0001098972) (Filer)

      6/6/25 4:05:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AGENUS INC (0001098972) (Filer)

      6/4/25 4:37:44 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

      Agenus Inc. (NASDAQ:AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases (NLM). Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of the global BATTMAN Phase 3 trial. The FDA waived the need for a BOT monotherapy arm, allowing for a simple two-arm study design. These new BOT/BAL data were reported at the 2025 ESMO Ga

      7/7/25 8:55:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

      Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab's unique FcγR-mediated immune activation underlying activity in refractory tumors Supports AI-enabled biomarker discovery, aligning with the national priorities and the FDA to expand access to personalized cancer treatment Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive biomark

      6/17/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces Virtual Annual Shareholders Meeting

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests. Webcast Information: Date: Tuesday, June 17, 2025 Time: 10:30 a.m. ET A live webcast and replay

      6/10/25 1:30:00 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Wright Timothy

      4 - AGENUS INC (0001098972) (Issuer)

      7/3/25 4:05:07 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Armen Garo H was granted 64,833 shares, increasing direct ownership by 33% to 258,842 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      6/30/25 4:30:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer O'Day Steven J was granted 43,497 shares, increasing direct ownership by 319% to 57,116 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      6/30/25 4:30:24 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 7:58:18 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 9:21:26 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      6/10/24 12:15:17 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agenus upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Agenus from Neutral to Buy and set a new price target of $25.00

      6/4/25 7:30:33 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

      7/19/24 7:27:15 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by William Blair

      William Blair downgraded Agenus from Outperform to Mkt Perform

      7/18/24 1:59:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      2/15/24 6:59:48 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      11/17/23 4:22:11 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Agenus Announces Appointment of Tom Harrison to Board of Directors

      Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

      8/8/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

      Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

      6/17/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Expands Executive Leadership Team

      Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

      7/20/23 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Financials

    Live finance-specific insights

    See more
    • Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

      $75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M equity investment at $7.50 per share Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as "Zydus," designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL). The strategic collaboration includes an exchange of Agenus' state-of-the-art biologics

      6/3/25 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Reports Q1 2025 Financial Results and Key Business Updates

      BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones Near-Term Capital Transaction Poised to Bolster Liquidity Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. "The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and

      5/12/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu

      4/29/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care